Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 AlteredExpression disease BEFREE BRAF-targeted paired box gene-8 (PAX8), a thyroid-specific transcription factor, generally dysregulated in BRAF-mutated thyroid cancer. 30760304 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Patients with RAIR, BRAF mutant thyroid cancer. 30256977 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Although most of the US Food and Drug Administration (FDA)-approved drugs are antiangiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. 31322645 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease BEFREE BRAFi inhibited ERK signaling in BRAF<sup>V600E</sup> mutants, but not BRAF wild-type thyroid cancer cell lines. 31097454 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease CTD_human Effects of curcumin and its adjuvant on TPC1 thyroid cell line. 30935902 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE We aimed to investigate the diagnostic value of the BRAF mutation in cytologically indeterminate thyroid nodules after the reclassification of a variant thyroid carcinoma. 30863114 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers. 31529211 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease BEFREE In this review, we provide an overview on the current knowledge concerning the mechanisms leading to resistance to BRAF inhibitors in human thyroid carcinomas and discuss the potential therapeutic strategies, including combinations of BRAF inhibitors with other targeted agents, which might be employed to overcome drug resistance and potentiate the activity of single agent BRAF inhibitors. 31540406 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions. 30481266 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E mutant thyroid cancer specimens, thereby promoting glycolysis. 30768848 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 AlteredExpression disease BEFREE In conclusion, the results of the current study suggest that BRAF<sup>V600E</sup>-induced KRT19 expression may promote thyroid cancer metastasis via EMT. 31289571 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease CTD_human A Toxicogenomic Approach Reveals a Novel Gene Regulatory Network Active in In Vitro and In Vivo Models of Thyroid Carcinogenesis. 30621213 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease BEFREE Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness. 30398411 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease BEFREE Combination strategies involving immune checkpoint inhibitors (ICIs) with tyrosine kinase (TK) or serine/threonine protein kinase B-raf (BRAF) inhibitors are showing considerable promise in the treatment of advanced thyroid cancer. 31412566 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 AlteredExpression disease BEFREE The mixed expression of BRAF under varying levels of differentiation may explain, in part, the contradictory studies regarding the impact of BRAF mutations on patient prognosis and also indicates a complex genomic signature for dedifferentiated thyroid cancer. 31229486 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE We further demonstrate that upfront combined inhibition of FAK and Src synergistically inhibits growth and invasion, and induces apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines. 30531837 2019
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. 30036146 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA. 29868707 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE However, the response to vemurafenib is limited in BRAF-mutant thyroid cancer. 29737325 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Papillary thyroid cancer (PTC) accounts for more than 97 % of thyroid cancer and 80% or more PTC cases harbor the BRAF mutation in Korea. 28258306 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. 29579361 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 Biomarker disease BEFREE The specific mechanisms of BRAF<sup>V600E</sup> and the unknown pathway associated with Mps1 exhibit potential for further study, and provide a theoretical basis for the molecular treatment of thyroid carcinoma. 29805692 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE A selective inhibitor of BRAF V600E has been proposed as a novel treatment for patients with thyroid cancer exhibiting BRAF V600E mutations. 29616135 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE Specimens of pituitary adenomas and thyroid cancer were collected for BRAF mutation assessments. 29593792 2018
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.600 GeneticVariation disease BEFREE TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases. 29435002 2018